Cargando…
COVID-19 and Hematologic Malignancies: Single Institution Analysis
Introduction COVID-19 in patients with hematologic malignancies are poorly characterized. Theoretically, it is believed that patients with malignancies having a significant chance of succumbing to COVID-19 due to the immunosuppression from the disease and myelosuppression from the cancer therapy com...
Autores principales: | Anusim, Nwabundo, Smalley, Melanie, Zimmer, Markie Sue, Lang, Doyle, Jindal, Vishal, Ahaneku, Hycienth O, Gupta, Ruby, Franklin, Candace, Jaiyesimi, Ishmael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330355/ http://dx.doi.org/10.1182/blood-2020-142784 |
Ejemplares similares
-
Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative Data Hub
por: Wood, William A., et al.
Publicado: (2020) -
Presentation, Management and Outcomes of COVID-19 Patients with Sickle Cell Disease
por: Anusim, Nwabundo, et al.
Publicado: (2020) -
Social and Demographic Factors Contributing to COVID-19 Vaccine Hesitancy in Patients with Hematologic Malignancies
por: Sweiss, Karen, et al.
Publicado: (2021) -
Clinical Outcomes of COVID-19 in Hematological Malignancies in Jordan : Tertiary Cancer Center Experience
por: Ababneh, Hazim, et al.
Publicado: (2021) -
COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies
por: Goksu, Suleyman Y, et al.
Publicado: (2021)